Health effects of the New Nordic Renal Diet in patients with stage 3 and 4 chronic kidney disease, compared with habitual diet: a randomized trial

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Health effects of the New Nordic Renal Diet in patients with stage 3 and 4 chronic kidney disease, compared with habitual diet : a randomized trial. / Misella Hansen, Nikita; Kamper, Anne Lise; Rix, Marianne; Feldt-Rasmussen, Bo; Leipziger, Jens; Sørensen, Mads Vaarby; Berg, Peder; Astrup, Arne; Salomo, Louise.

In: American Journal of Clinical Nutrition, Vol. 118, No. 5, 2023, p. 1042-1054.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Misella Hansen, N, Kamper, AL, Rix, M, Feldt-Rasmussen, B, Leipziger, J, Sørensen, MV, Berg, P, Astrup, A & Salomo, L 2023, 'Health effects of the New Nordic Renal Diet in patients with stage 3 and 4 chronic kidney disease, compared with habitual diet: a randomized trial', American Journal of Clinical Nutrition, vol. 118, no. 5, pp. 1042-1054. https://doi.org/10.1016/j.ajcnut.2023.08.008

APA

Misella Hansen, N., Kamper, A. L., Rix, M., Feldt-Rasmussen, B., Leipziger, J., Sørensen, M. V., Berg, P., Astrup, A., & Salomo, L. (2023). Health effects of the New Nordic Renal Diet in patients with stage 3 and 4 chronic kidney disease, compared with habitual diet: a randomized trial. American Journal of Clinical Nutrition, 118(5), 1042-1054. https://doi.org/10.1016/j.ajcnut.2023.08.008

Vancouver

Misella Hansen N, Kamper AL, Rix M, Feldt-Rasmussen B, Leipziger J, Sørensen MV et al. Health effects of the New Nordic Renal Diet in patients with stage 3 and 4 chronic kidney disease, compared with habitual diet: a randomized trial. American Journal of Clinical Nutrition. 2023;118(5):1042-1054. https://doi.org/10.1016/j.ajcnut.2023.08.008

Author

Misella Hansen, Nikita ; Kamper, Anne Lise ; Rix, Marianne ; Feldt-Rasmussen, Bo ; Leipziger, Jens ; Sørensen, Mads Vaarby ; Berg, Peder ; Astrup, Arne ; Salomo, Louise. / Health effects of the New Nordic Renal Diet in patients with stage 3 and 4 chronic kidney disease, compared with habitual diet : a randomized trial. In: American Journal of Clinical Nutrition. 2023 ; Vol. 118, No. 5. pp. 1042-1054.

Bibtex

@article{958a56167c454a7aa25df2cc7352841a,
title = "Health effects of the New Nordic Renal Diet in patients with stage 3 and 4 chronic kidney disease, compared with habitual diet: a randomized trial",
abstract = "Background: Chronic kidney disease (CKD) leads to an accumulation of waste products and causes adverse cardiometabolic effects. Objectives: We investigated the health effects of the New Nordic Renal Diet (NNRD), a novel meal pattern reduced in phosphorus, protein, and sodium. Methods: A 26-wk randomized trial compared the NNRD with a habitual diet. The NNRD group received weekly home deliveries of food and recipes. Monthly study visits included fasting blood samples, 24-h urine samples, blood pressure, and anthropometric measurements. Intention-to-treat analysis used linear mixed-effects models. Results: Sixty patients, mean estimated glomerular filtration rate (eGFR) 34 mL/min/1.73 m2 and body mass index of 25–27 kg/m2, were included and 58 completed. Metabolic syndrome was present in 53% (NNRD group) and 57% (control group). The NNRD group (n = 30) reduced their 24-h urine phosphorus excretion by 19% (−153 mg; 95% confidence interval [CI]: −210, −95), control group (n = 30) (no change), between-group difference −171 mg (95% CI: −233, −109; P < 0.001). Proteinuria was reduced by 39% in the NNRD group (−0.33 g/d; 95% CI: −0.47, −0.18), control group (no change), between-group difference −0.34 g/d (95% CI: −0.52, −0.17; P < 0.001). Plasma urea was reduced by −1.5 mmol/L in the NNRD group (95% CI: −2.1, −0.9), control group (no change), between-group difference −1.4 mmol/L (95% CI: −2.0, −0.7; P < 0.001). Systolic blood pressure fell by −5.2 mmHg in the NNRD group (95% CI: −8.4, −2.1), control group (no change), between-group difference −3.9 mmHg (95% CI; −7.6, −0.2; P = 0.04). The NNRD group lost −1.7 kg (95% CI: −2.6, −0.8), control group (no change), between-group difference −2.0 kg (95% CI: −3.0, −1.0; P < 0.001). There were no effects on eGFR during the 26-wk intervention. Conclusion: NNRD in moderate CKD reduces phosphorus excretion, proteinuria, systolic blood pressure, and weight, mainly by reducing abdominal fat. This trial was registered at clinicaltrials.gov as NCT04579315.",
keywords = "24h urine phosphorus, acid base, blood pressure, chronic kidney disease, dietary intervention, low dietary protein, low dietary sodium, metabolic syndrome, New Nordic Renal Diet, proteinuria, weight loss",
author = "{Misella Hansen}, Nikita and Kamper, {Anne Lise} and Marianne Rix and Bo Feldt-Rasmussen and Jens Leipziger and S{\o}rensen, {Mads Vaarby} and Peder Berg and Arne Astrup and Louise Salomo",
note = "Publisher Copyright: {\textcopyright} 2023 The Authors",
year = "2023",
doi = "10.1016/j.ajcnut.2023.08.008",
language = "English",
volume = "118",
pages = "1042--1054",
journal = "American Journal of Clinical Nutrition",
issn = "0002-9165",
publisher = "American Society for Nutrition",
number = "5",

}

RIS

TY - JOUR

T1 - Health effects of the New Nordic Renal Diet in patients with stage 3 and 4 chronic kidney disease, compared with habitual diet

T2 - a randomized trial

AU - Misella Hansen, Nikita

AU - Kamper, Anne Lise

AU - Rix, Marianne

AU - Feldt-Rasmussen, Bo

AU - Leipziger, Jens

AU - Sørensen, Mads Vaarby

AU - Berg, Peder

AU - Astrup, Arne

AU - Salomo, Louise

N1 - Publisher Copyright: © 2023 The Authors

PY - 2023

Y1 - 2023

N2 - Background: Chronic kidney disease (CKD) leads to an accumulation of waste products and causes adverse cardiometabolic effects. Objectives: We investigated the health effects of the New Nordic Renal Diet (NNRD), a novel meal pattern reduced in phosphorus, protein, and sodium. Methods: A 26-wk randomized trial compared the NNRD with a habitual diet. The NNRD group received weekly home deliveries of food and recipes. Monthly study visits included fasting blood samples, 24-h urine samples, blood pressure, and anthropometric measurements. Intention-to-treat analysis used linear mixed-effects models. Results: Sixty patients, mean estimated glomerular filtration rate (eGFR) 34 mL/min/1.73 m2 and body mass index of 25–27 kg/m2, were included and 58 completed. Metabolic syndrome was present in 53% (NNRD group) and 57% (control group). The NNRD group (n = 30) reduced their 24-h urine phosphorus excretion by 19% (−153 mg; 95% confidence interval [CI]: −210, −95), control group (n = 30) (no change), between-group difference −171 mg (95% CI: −233, −109; P < 0.001). Proteinuria was reduced by 39% in the NNRD group (−0.33 g/d; 95% CI: −0.47, −0.18), control group (no change), between-group difference −0.34 g/d (95% CI: −0.52, −0.17; P < 0.001). Plasma urea was reduced by −1.5 mmol/L in the NNRD group (95% CI: −2.1, −0.9), control group (no change), between-group difference −1.4 mmol/L (95% CI: −2.0, −0.7; P < 0.001). Systolic blood pressure fell by −5.2 mmHg in the NNRD group (95% CI: −8.4, −2.1), control group (no change), between-group difference −3.9 mmHg (95% CI; −7.6, −0.2; P = 0.04). The NNRD group lost −1.7 kg (95% CI: −2.6, −0.8), control group (no change), between-group difference −2.0 kg (95% CI: −3.0, −1.0; P < 0.001). There were no effects on eGFR during the 26-wk intervention. Conclusion: NNRD in moderate CKD reduces phosphorus excretion, proteinuria, systolic blood pressure, and weight, mainly by reducing abdominal fat. This trial was registered at clinicaltrials.gov as NCT04579315.

AB - Background: Chronic kidney disease (CKD) leads to an accumulation of waste products and causes adverse cardiometabolic effects. Objectives: We investigated the health effects of the New Nordic Renal Diet (NNRD), a novel meal pattern reduced in phosphorus, protein, and sodium. Methods: A 26-wk randomized trial compared the NNRD with a habitual diet. The NNRD group received weekly home deliveries of food and recipes. Monthly study visits included fasting blood samples, 24-h urine samples, blood pressure, and anthropometric measurements. Intention-to-treat analysis used linear mixed-effects models. Results: Sixty patients, mean estimated glomerular filtration rate (eGFR) 34 mL/min/1.73 m2 and body mass index of 25–27 kg/m2, were included and 58 completed. Metabolic syndrome was present in 53% (NNRD group) and 57% (control group). The NNRD group (n = 30) reduced their 24-h urine phosphorus excretion by 19% (−153 mg; 95% confidence interval [CI]: −210, −95), control group (n = 30) (no change), between-group difference −171 mg (95% CI: −233, −109; P < 0.001). Proteinuria was reduced by 39% in the NNRD group (−0.33 g/d; 95% CI: −0.47, −0.18), control group (no change), between-group difference −0.34 g/d (95% CI: −0.52, −0.17; P < 0.001). Plasma urea was reduced by −1.5 mmol/L in the NNRD group (95% CI: −2.1, −0.9), control group (no change), between-group difference −1.4 mmol/L (95% CI: −2.0, −0.7; P < 0.001). Systolic blood pressure fell by −5.2 mmHg in the NNRD group (95% CI: −8.4, −2.1), control group (no change), between-group difference −3.9 mmHg (95% CI; −7.6, −0.2; P = 0.04). The NNRD group lost −1.7 kg (95% CI: −2.6, −0.8), control group (no change), between-group difference −2.0 kg (95% CI: −3.0, −1.0; P < 0.001). There were no effects on eGFR during the 26-wk intervention. Conclusion: NNRD in moderate CKD reduces phosphorus excretion, proteinuria, systolic blood pressure, and weight, mainly by reducing abdominal fat. This trial was registered at clinicaltrials.gov as NCT04579315.

KW - 24h urine phosphorus

KW - acid base

KW - blood pressure

KW - chronic kidney disease

KW - dietary intervention

KW - low dietary protein

KW - low dietary sodium

KW - metabolic syndrome

KW - New Nordic Renal Diet

KW - proteinuria

KW - weight loss

U2 - 10.1016/j.ajcnut.2023.08.008

DO - 10.1016/j.ajcnut.2023.08.008

M3 - Journal article

C2 - 37598748

AN - SCOPUS:85171384471

VL - 118

SP - 1042

EP - 1054

JO - American Journal of Clinical Nutrition

JF - American Journal of Clinical Nutrition

SN - 0002-9165

IS - 5

ER -

ID: 375051253